Deerfield, IL - Astellas Pharma announced that the US Food and Drug Administration (FDA) has approved conivaptan hydrochloride injection (Vaprisol), an arginine vasopressin antagonist, for the ...

Please provide your email address to receive an email when new articles are posted on . The FDA’s Cardiovascular and Renal Drugs Advisory Committee today did not recommend approval of lixivaptan for ...

Navigation programs' impact in a Colombian breast cancer patients cohort. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a full text component.

As a general rule, the treatment of hyponatremia should be directed at the primary underlying disorder because such treatment might, in itself, correct the electrolyte imbalance. Thiazide diuretics ...

Hyponatremia: An Update on the Management of SIADH Therapeutic options for SIADH have been significantly enhanced with the introduction of specific vasopressin receptor antagonists HOW TO TAKE THE ...

VAPRISOL (conivaptan) 20mg/ampule by Astellas Pharma A premixed formulation of Vaprisol (conivaptan HCl injection, from Astellas) has been approved for the treatment of hospitalized patients with ...

The FDA has approved an intravenous drug for hospital patients suffering from potentially life-threateningly low sodium levels, the drug's manufacturer said Friday. Astellas Pharma US Inc. said it ...

FDA Approves Astellas Pharma's Vaprisol for the Treatment of Hypervolemic Hyponatremia DEERFIELD, Ill., March 2 -- Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration ...

The treatment of hyponatremia has largely consisted of identifying and treating the underlying cause, such as correcting volume depletion and eliminating any offending medications. In situations where ...

The term hyponatremia refers to a condition where the blood level of the electrolyte sodium is too low. A healthy sodium level is between 135 and 145 mmol/l and a person is considered to be ...